By using its sophisticated, proprietary platform, Epitopea is capable of identifying markers (called antigens) that are physically presented on the surface of cancer cells and thus recognisable by the immune system. By selecting those markers that are specific to cancer and shared between different patients, Epitopea is seeking to create novel, safe, off-the-shelf cancer vaccines capable of training the immune system to recognise these markers and attack the cells that present them.
We were born out of a unique relationship with the University of Cambridge and we maintain privileged access to its most inspiring ideas and people in life sciences and deep tech.
© 2022 Cambridge Innovation Capital.
All rights reserved
Terms | Privacy | Cookie Policy | ESG Policy